Company Overview
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +161.99% |
| 6 Months: | -22.26% |
| 3 Months: | +1.95% |
| 1 Month: | -20.58% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.20 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 70.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GLMD Galmed Pharmaceuticals Ltd. PHARMA | 3.82 | -0.27 | $4.08M | 0.00% | -53.92% | -68.21% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 1.26M | 2.11M | 2.10M | 3.04M | 2.04M |
| Operating Income | - | -1.26M | -2.11M | -2.10M | -3.04M | -2.04M |
| EBITDA | - | -1.26M | -2.11M | -2.10M | -3.04M | -2.04M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -1.10M | -2.50M | -1.89M | -4.82M | -1.91M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -1.10M | -2.50M | -1.89M | -4.82M | -1.91M |
| Diluted EPS | - | -0.62 | -0.63 | -0.33 | - | -0.29 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 17.65M | 7.49M | 6.28M | 8.51M |
| Operating Income | -17.65M | -7.49M | -6.28M | -8.51M |
| EBITDA | -17.62M | -7.46M | -6.20M | -8.51M |
| Interest Expense | - | - | - | - |
| Pretax Income | -17.87M | -6.91M | -7.52M | -10.31M |
| Tax Provision | - | - | - | - |
| Net Income | -17.87M | -6.91M | -7.52M | -10.31M |
| Diluted EPS | -127.80 | -30.00 | -8.08 | -2.39 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 16.56M | 16.63M | 18.50M | 18.63M |
| Current Assets | - | 14.72M | 13.24M | 16.12M | 18.63M |
| Cash & Equivalents | - | 2.02M | 2.86M | 4.65M | 3.98M |
| Inventory | - | - | - | - | - |
| Receivables | - | 157.00K | 165.00K | 209.00K | 80.00K |
| Total Liabilities | - | 3.14M | 2.75M | 2.17M | 2.85M |
| Current Liabilities | - | 3.09M | 2.75M | 2.17M | 2.85M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | 229.00K | 215.00K | 41.00K | 0 | - |
| Total Equity | - | 13.42M | 13.88M | 16.33M | 15.78M |
| Shares Outstanding | - | 140.02K | 420.44K | 1.66M | 6.58M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -18.50M | -6.14M | -5.88M | -6.32M |
| Investing Cash Flow | - | 17.56M | 800.00K | -1.11M | -3.38M |
| Financing Cash Flow | - | 70.00K | 6.18M | 8.79M | 9.03M |
| Capital Expenditure | -11.00K | -4.00K | - | - | - |
| Free Cash Flow | - | -18.50M | -6.14M | -5.88M | -6.32M |
| Net Change in Cash | - | -868.00K | 848.00K | 1.79M | -664.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | -133.1% | -49.8% | -46.0% | -65.3% |
| ROCE % | -131.1% | -54.0% | -38.5% | -53.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 1.04% | 10.86K | $50.26K |
| 2 | HRT Financial LP | 0.51% | 5.26K | $24.36K |
| 3 | Xtx Topco Ltd | 0.18% | 1.88K | $8.69K |
| 4 | Two Sigma Securities, LLC | 0.13% | 1.38K | $6.38K |
| 5 | Royal Bank of Canada | 0.01% | 69 | $319 |
| 6 | SBI Securities Co., Ltd. | - | 8 | $37 |
| 7 | Morgan Stanley | - | 7 | $32 |
| 8 | Wells Fargo & Company | - | 5 | $23 |
| 9 | Federation Des Caisses Desjardins Du Quebec | - | 2 | $9 |
| 10 | Tsfg, Llc | - | 2 | $9 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GLMD
Galmed (NASDAQ: GLMD) regains Nasdaq $1 bid-price compliance - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPbHNwajEtVTJFUjJmLVRNT0hNdVpGWTVMcFFoamFlWE5uTk1ycENORTdxSEEyNUtsMFdKMW04MFVLaFJJWjUyMmdvUkVIODhqMkxsYUVmSFFIYnB5UXV2MXQyWlFleDlLaHhHa3VuRFM1Z2ZKQmlfYmZyT01XMnJ5blhUM3NITGFRUUZ5cm…
Galmed Pharmaceuticals: Q2 Earnings Snapshot - kare11.com
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOeEpyNGFSZWRIS1ZuQ3ItOWhFa1NHVVRuQnJ4UXVITklweHBvaXlET2N1SjMxLVZlS1NoOUpDbFM5VWxqQWtVajBjRnllOVd3Qkh2eEw0TXoyVHprU0V0LWx6YkM3ZnViWFdlei1Qckh2SHJGX0Z2ZS1mcXdlME45WVhHMGxKMVg0NWI3bV…
GLMD Stock Shot Up 55% Today After Rising 27% In 5 Days – What’s The Latest On Its Parkinson’s Disease Therapy? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxQQV9TQVJzTTdrNzE0bXRZX3BSU01OV1MzM3ZZcEhUM1l6UlVacW93cURWemo5RnJRZFZtQUxkRTdvRE5LcnJYLU5GWnNjUHB5aE8zd2piNXBzSmNEUVlOSThONHBNaXltQ3lIanJRMTg5TERfVTBCbTNtNm5TSUItQ0pNNUswTUkxZGlFbU…
Galmed Pharmaceuticals Ltd. SEC Filing (Sep 4, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNS2ozdUJEbHJrVjc4V2lJeDdPNzI1aWtLVDd5eTJ3OExjV0FiT19iQ0pEelhNcElOU0R4Q1NfVlRhUUE3aHNtUWdLdXdCczdydEZZM1ppUDQtejlGRVdQNE5EY2JYVXlKNWVqMkRYX3MybmlsVWJqbmZQSFY4SDJaekVQSWhaTTZ2MmpPbD…
Galmed Stock Soars On Brain-Penetrating Aramchol Formulation - Galmed Pharmaceuticals (NASDAQ:GLMD) - Benzinga
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPWW5YS2hTamtvaVpCUmwzd2FvTzlEeEM2OUpWSmZTMXRCZVRybmJ2OVlmdHRxR3pDQUZHQ2tUNHA2SGRHWjRSMnNneFRPR1F5MHB6NjhleVN3TXNzcHJGcHRXNDFPNWtQZm1FRFJZYmlOVTk2cllwZGZRa0Z0aU1JMXZMbFE0ek9CaWRjUH…
Galmed Pharmaceuticals Ltd. Revenue Breakdown – NASDAQ:GLMD - tradingview.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBLUkQxTkVkZHNPMDRTci1Ddk5hLTFiV0ZZRnZ3WTRQb05FeG02bDFDbTlUNTRyZGZkOFlGTUgtZWV1WTA3YWJaRS14QlFBTm9UR1VBX196WUo3M1ZObzBSNmIxREtjMW8xRjdhcVFObGNtUy1FRVNV?oc=5" target="_blank">Galmed …
GLMD — Frequently Asked Questions
What is the current share price of Galmed Pharmaceuticals Ltd. (GLMD)?
As of 2026-09-19 21:16 PDT, Galmed Pharmaceuticals Ltd. (GLMD) trades at $3.82 on NasdaqCM. Its 52-week range is $1.27 to $12.88.
What is the market capitalisation of GLMD?
Galmed Pharmaceuticals Ltd. (GLMD) has a market capitalisation of $4.08M on NasdaqCM.
What is the P/E ratio of GLMD?
GLMD trades at a trailing price-to-earnings (P/E) ratio of -0.27. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.36.
What is the return on equity (ROE) of GLMD?
GLMD has a return on equity (ROE) of -68.21%. Its return on capital employed (ROCE) is -53.92%.
Is GLMD a good stock to buy?
This page provides a data-driven analysis of Galmed Pharmaceuticals Ltd. (GLMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.